SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Lithera, Inc. ("Lithera" or "the Company"), a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that George Mahaffey, President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4th at 10:00 AM Eastern Time. The conference will be held at the Boston Marriott Copley Place in Boston, MA.
Lithera is a clinical stage company developing pharmaceutical products addressing both lifestyle and medical indications in aesthetic medicine and ophthalmology. Using FDA-registered drugs approved for use in other indications, Lithera's products target and stimulate natural fat tissue metabolism to achieve non-ablative, non-surgical fat tissue reduction in specific locations. Our lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection), is a novel injectable pharmaceutical product designed to produce local, selective, non-ablative fat tissue reduction (pharmaceutical lipoplasty). LIPO-202 is currently under development for the reduction of central abdominal bulging in non-obese patients (BMI less than 30 kg/m2). LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate for Injection) is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (also known as Graves' Orbitopathy). Founded in 2007, the Company has assembled an exceptional team of senior executives, employees and advisors and has been financed by top-tier venture capital firms. For more information on Lithera, Inc., please visit www.lithera.com.
Lithera, LIPO-102, LIPO-202 and the Lithera logo are trademarks or registered trademarks of Lithera, Inc. Other names and brands may be claimed as the property of others.